Astellas Eschews Foreign Acquisitions As Rivals Go On Buying Spree
This article was originally published in PharmAsia News
While other Japanese drug makers embarked on an acquisition spree the past year, Astellas Pharma has remained on the sidelines. The company did so even though two of its major drugs that together account for a third of its annual revenues have either lost their patent protection already or soon will do so. Astellas says it is considering licensing agreements as well as acquisitions to build its pipeline in several areas, but one analyst said the firm, despite its $3 billion in cash, still needs to find an acquisition target that works for it. (Click here for more
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.